新・血栓止血血管学　抗凝固と線溶

出版社： 金芳堂
著者：
発行日： 2015-10-20
分野： 臨床医学：内科  >  血液
ISBN： 9784765316507
シリーズ： 新・血栓止血血管学
電子書籍版： 2015-10-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,720 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,720 円(税込)

購入する

目次

  • 新・血栓止血血管学　抗凝固と線溶

    ―目次―

    1部　抗凝固反応
    　1．血栓と抗凝固系：オーバービュー
    　2．トロンボモジュリンの基礎と臨床
    　3．プロテインC、プロテインS、
    　　　血管内皮プロテインCレセプターの基礎と臨床
    　4．アンチトロンビンの基礎と臨床：
    　　　ヘパリンコアファクターを含む
    　5．組織因子経路阻害因子の基礎と臨床
    　6．プロテインZとプロテインZ依存性プロテアーゼインヒビター

    2部　線溶反応
    　7．線溶機構と血栓症：オーバービュー
    　8．プラスミノゲン
    　9．プラスミノゲンアクチベーターとその受容体
    　10．血管内皮細胞と線溶活性調節
    　11．α2-プラスミン・インヒビターと
    　　　　ヒスチジンリッチ・グリコプロテイン
    　12．PAI-1
    　13．TAFIの基礎と臨床
    　14．TAFla阻害薬の開発に向けたアプローチ
    　15．癌と細胞性線溶
    　16．Polyhedrocytes：その意味論―病理と治療へのインパクト

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1部 抗凝固反応

P.9 掲載の参考文献
1) Gould TJ, Lysov Z, Liaw PC. Extracellular DNA and histones : double-edged swords in immunothrombosis. J Thromb Haemost 2015 ; 13 (Suppl 1) : S82-S91.
 
2) X. Long Zheng. DNase, ADAMTS13, and iPAD4 : good for the heart. Blood. 2014 ; 123 (1) : 10-11.
PubMed
3) Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990 ; 82 (3 Suppl) : II47-59.
 
4) Wakefield TW, Myers DD, Henke PK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol 2008 ; 28 : 387-391.
PubMed
5) Ito T, Maruyama I, Thrombomodulin : protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost. 2011 ; 9 Suppl 1 : 168-173.
 
P.21 掲載の参考文献
1) Suzuki K, Kusumoto H, Deyashiki Y, et al. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 1987 ; 6 : 1891-1897.
PubMed
2) Zushi M, Gomi K, Yamamoto S, et al. The last three consecutive epidermal growth factor-like structures of human thrombomodulin comprise the minimum functional domain for protein C-activating cofactor activity and antithrombin activity. J Biol Chem 1989 ; 264 : 10351-10353.
 
3) Koyama T, Parkinson JF, Aoki N, et al. Relationship between post-translational glycosylation and anticoagulant function of secretable recombinant mutants of human thrombomodulin. Br J Haematol 1991 ; 78 : 515-522.
PubMed
4) Izumikawa T, Kitagawa H. Amino acid sequence surrounding the chondroitin sulfate attachment site of thrombomodulin regulates chondroitin polymerization. Biochem Biophys Res Comm 2015 ; 460 : 233-237.
PubMed
5) David-Dufilho M, Millanvoye-Van Brussel E, Topal G, et al. Endothelial thrombomodulin induces Ca2+ signals and nitric oxide synthesis through epidermal growth factor receptor kinase and calmodulin kinase II. J Biol Chem 2005 ; 280 : 35999-36006.
 
6) 岡田雅彦, 船越康智, 冨永典男, 他. 胎生期より血栓症を認める先天性トロンボモジュリン異常症の1例. 日本血栓止血学会雑誌 (第30回学術集会抄録集) 2007 ; 18 : 470.
 
7) Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009 ; 361 (4) : 345-357.
PubMed
8) Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem 2010 ; 17 : 2059-2069.
PubMed
9) Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009 ; 15 : 1318-1321.
 
10) Ma CY, Chang WE, Shi GY, et al. Recombinant thrombomodulin inhibits lipopolysaccharide-induced inflammatory response by blocking the functions of CD14. J Immunol 2015 ; 194 : 1905-1915.
PubMed
11) Ito T, Kawahara K, Okamoto K, et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008 ; 28 : 1825-1830.
PubMed
12) Suzuki K, Hayashi T, Nishioka J, et al. A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. J Biol Chem 1989 ; 264 : 4872-4876.
PubMed
13) van Iersel T, Stroissnig H, Giesen P, et al. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 2011 ; 105 : 302-312.
PubMed
14) Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007 ; 5 : 31-41.
PubMed
15) Mimuro J, Takahashi H, Kitajima I, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res 2013 ; 131 (5) : 436-443.
PubMed
16) Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis : a systematic review and meta-analysis. J Thromb Haemost 2015 ; 13 : 508-519.
PubMed
P.28 掲載の参考文献
1) Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008 ; 112 (1) : 19-27.
 
2) Mosnier LO, Griffin JH. Protein C, Protein S, Thrombomodulin, and the Endothelial Protein C Receptor Pathways. In : Marder VJ, Aird WC, Bennett JS, et al. Hemostasis and thrombosis : basic principles and clinical practice. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins ; 2013 : 300-313.
 
3) Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998 ; 102 (8) : 1481-1488.
PubMed
4) Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013 ; 11 Suppl 1 : 242-253.
 
5) Bae JS, Yang L, Rezaie AR. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci U S A 2007 ; 104 (8) : 2867-2872.
PubMed
6) Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005 ; 105 (8) : 3178-3184.
PubMed
7) Minhas N, Xue M, Fukudome K, et al. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 2010 ; 24 (3) : 873-881.
PubMed
8) Mosnier LO, Sinha RK, Burnier L, et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood 2012 ; 120 (26) : 5237-5246.
PubMed
9) Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012 ; 366 (22) : 2055-2064.
PubMed
10) Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency : a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995 ; 73 (5) : 876-889.
 
11) 津田博子. 先天性プロテインC欠乏症と先天性プロテインS欠乏症. 血液フロンティア 2015 ; 25 (1) : 29-35.
 
12) Tang L, Guo T, Yang R, et al. Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in chinese population. PLoS One 2012 ; 7 (4) : e35773.
PubMed
13) Tang L, Lu X, Yu JM, et al. PROC c.574_576del polymorphism : a common genetic risk factor for venous thrombosis in the Chinese population. J Thromb Haemost 2012 ; 10 (10) : 2019-2026.
 
14) Kinoshita S, Iida H, Inoue S, et al. Protein S and protein C gene mutations in Japanese deep vein thrombosis patients. Clin Biochem 2005 ; 38 (10) : 908-915.
PubMed
15) Dahlback B. C4b-binding protein : a forgotten factor in thrombosis and hemostasis. Semin Thromb Hemost 2011 ; 37 (4) : 355-361.
PubMed
16) Carlsson S, Dahlback B. Dependence on vitamin K-dependent protein S for eukaryotic cell secretion of the beta-chain of C4b-binding protein. J Biol Chem 2010 ; 285 (42) : 32038-32046.
PubMed
17) He X, Shen L, Villoutreix BO, et al. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem 1998 ; 273 (42) : 27449-27458.
PubMed
18) Wood JP, Ellery PE, Maroney SA, et al. Biology of tissue factor pathway inhibitor. Blood 2014 ; 123 (19) : 2934-2943.
 
19) Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006 ; 103 (9) : 3106-3111.
PubMed
20) Heeb MJ, Rosing J, Bakker HM, et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci U S A 1994 ; 91 (7) : 2728-2732.
PubMed
21) van der Meer JH, van der Poll T, van't Veer C. TAM receptors, Gas6, and protein S : roles in inflammation and hemostasis. Blood 2014 ; 123 (16) : 2460-2469.
PubMed
22) Saller F, Brisset AC, Tchaikovski SN, et al. Generation and phenotypic analysis of protein S-deficient mice. Blood 2009 ; 114 (11) : 2307-2314.
PubMed
23) Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 2009 ; 119 (10) : 2942-2953.
PubMed
24) Zoller B, Garcia de Frutos P, Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood. 1995 ; 85 (12) : 3524-3531.
PubMed
25) Comp PC, Thurnau GR, Welsh J, et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986 ; 68 (4) : 881-885.
PubMed
26) Tsuda T, Jin X, Tsuda H, et al. New quantitative total protein S-assay system for diagnosing protein S type II deficiency : clinical application of the screening system for protein S type II deficiency. Blood Coagul Fibrinolysis 2012 ; 23 (1) : 56-63.
PubMed
27) Gandrille S, Borgel D, Ireland H, et al. Protein S deficiency : a database of mutations. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997 ; 77 (6) : 1201-1214.
 
28) Kimura R, Honda S, Kawasaki T, et al. Protein S-K196E mutation as a genetic risk factor for deep vein thrombosis in Japanese patients. Blood 2006 ; 107 (4) : 1737-1738.
PubMed
29) Ikejiri M, Wada H, Sakamoto Y, et al. The association of protein S Tokushima-K196E with a risk of deep vein thrombosis. Int J Hematol 2010 ; 92 (2) : 302-305.
PubMed
30) Liu W, Yin T, Okuda H, et al. Protein S K196E mutation, a genetic risk factor for venous thromboembolism, is limited to Japanese. Thromb Res 2013 ; 132 (2) : 314-315.
PubMed
31) Hamasaki N, Kuma H, Tsuda H. Activated protein C anticoagulant system dysfunction and thrombophilia in Asia. Ann Lab Med 2013 ; 33 (1) : 8-13.
PubMed
32) Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor : a multiliganded and multifunctional receptor. Blood 2014 ; 124 (10) : 1553-1562.
PubMed
33) Lopez-Sagaseta J, Puy C, Tamayo I, et al. sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove. Blood 2012 ; 119 (12) : 2914-2921.
PubMed
34) Gu JM, Crawley JT, Ferrell G, et al. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 2002 ; 277 (45) : 43335-43343.
PubMed
35) Kurosawa S, Stearns-Kurosawa DJ, Carson CW, et al. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus : lack of correlation with thrombomodulin suggests involvement of different pathological processes. Blood 1998 ; 91 (2) : 725-727.
PubMed
36) Qu D, Wang Y, Esmon NL, et al. Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. J Thromb Haemost 2007 ; 5 (2) : 395-402.
PubMed
37) Biguzzi E, Merati G, Liaw PC, et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost 2001 ; 86 (4) : 945-948.
PubMed
38) Kendirli T, Ciftci E, Ince E, et al. Homozygous 23-bp insertion of endothelial protein c receptor gene in a child with fatal sepsis. Pediatr Hematol Oncol 2007 ; 24 (3) : 199-204.
 
39) Medina P, Navarro S, Bonet E, et al. Functional analysis of two haplotypes of the human endothelial protein C receptor gene. Arterioscler Thromb Vasc Biol 2014 ; 34 (3) : 684-690.
PubMed
P.36 掲載の参考文献
1) 辻肇. ATの基礎と臨床. In : 一瀬白帝, 編. 図説 血栓・止血・血管学 血栓症制圧のために. 東京 : 中外医学社, 2005 : 483-489.
 
2) Li W, Johnson DJ, Esmon CT, et al. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004 ; 11 : 857-862.
PubMed
3) Oosta GM, Gardner WT, Beeler DL, et al. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A 1981 ; 78 : 829-833.
PubMed
4) Rosenberg RD. Regulation of the hemostatic mechanisms. In : Stamatoyannopoulos G, ed. The Molecular Basis of Blood Deseases. Philadelphia : Saunders, 1987 : 530-550.
 
5) Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965 ; 13 : 516. Abstract.
 
6) Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000 ; 106 : 873-878.
PubMed
7) Kato I, Takagi Y, Ando Y, et al. A complex genomic abnormality found in a patient with antithrombin deficiency and autoimmune disease-like symptoms. Int J Hematol 2014 ; 100 : 200?205.
 
8) Gu W, Zhang F, Lupski JR. Mechanisms for human genomic rearrangements. Pathogenetics 2008 ; 1 (1) : 4.
PubMed
9) Patnaik MM, Moll S. Inherited antithrombin deficiency : a review. Haemophilia 2008 ; 14 : 1229-1239.
PubMed
10) Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001 ; 345 : 165-169.
 
11) 小出武比古. ヘパリンコファクターIIの基礎と臨床. In : 一瀬白帝, 編. 図説 血栓・止血・血管学 血栓症制圧のために. 東京 : 中外医学社, 2005 : 490-497.
 
12) Van Deerlin VM, Tollefsen DM. The N-terminal acidic domain of heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J Biol Chem 1991 ; 266 : 20223-20231.
 
13) Villa P, Aznar J, Vaya A, et al. Hreditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost 1999 ; 82 : 1011-1014.
 
14) Kanagawa Y, Shigekiyo T, Aihara K, et al. Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site : HC II Tokushima. Thromb Haemost 2001 ; 85 : 101-107.
PubMed
15) Kondo S, Tokunaga F, Kario K, et al. Molecular and cellular basis for type I heparin cofactor II deficiency (heparin cofactor II Awaji). Blood 1996 ; 87 : 1006-1012.
PubMed
16) Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II-deficient mice. Blood 2007 ; 110 : 4261-4267.
PubMed
P.42 掲載の参考文献
1) 加藤久雄. TFPIの基礎と臨床. In : 一瀬白帝編. 図説血栓・止血・血管学 : 血栓症制圧のために. 東京 : 中外医学社 2005 : 498-509.
 
2) Wood JP, Ellery PER, Maroney SA, et al. Biology of tissue factor pathway inhibitor. Blood 2014 : 123 : 2934-2943.
PubMed
3) Chang JY, Monroe DM, Oliver JA, et al : TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 1999 ; 81 : 45-49.
PubMed
4) Zhang J, Orland P, Lu L, et al. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003 ; 108 : 623-627.
 
5) Hackeng TM, Sere KM, Tans G, et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A. 2006 ; 103 : 3106-3111.
PubMed
6) Wood JP, Ellery PE, Maroney SA, et al. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2014 ; 34 : 169-176.
 
7) Wood JP, Bunce MW, Maroney SA, et al. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A. 2013 ; 110 : 17838-17843.
PubMed
8) Hamaru T, Kamikubo Y, Nakahara Y, et al. Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett 1998 ; 421 : 197-202.
 
9) Kamikubo Y Nakahara Y, Takemoto S, et al. Human recombinant tissue factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997 ; 407 : 116-120.
PubMed
10) Shimura M, Wada H, Wakita Y, et al. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996 ; 52 : 165-170.
PubMed
11) Shimura M, Wada H, Yamamura M, et al. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1999 ; 60 : 94-98.
 
12) Okugawa Y, Wada H, Noda T, et al. Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation. Am J Hematol 2000 ; 65 : 210-214
 
13) Kobayashi M, Wada H, Wakita Y, et al. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995 ; 73 : 10-14.
PubMed
14) Dahm A, Van Hylckama Vlieg A, Bendz B, et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003 ; 101 : 4387-4392.
PubMed
15) Morange PE, Simon C, Alessi MC, et al. Endothelial cell markers and the risk of coronary heart disease : the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004 ; 109 : 1343-1348.
PubMed
16) Harris GM, Stendt CL, Vollenhoven BJ, et al. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol. 1999 ; 60 : 175-180.
PubMed
17) Broze GJ Jr, Lange GW, Duffin KL, et al. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994 ; 5 : 551-559.
PubMed
18) Novotny WF, Palmier M, Wun TC, et al : Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 1991 ; 78 : 394-400.
PubMed
19) Sandset PM, Warn-Cramer BJ, Rao LV, et al. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor : evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA. 1991 ; 88 : 708-712.
PubMed
20) Maroney SA, Cooley BC, Sood R, et al. Combined tissue factor pathway inhibitor and thrombomodulin deficiency produces an augmented hypercoagulable state with tissue-specific fibrin deposition. J Thromb Haemost 2008 ; 6 : 111-117.
PubMed
21) Eitzman DT, Westrick RJ, Bi X, et al. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden. Circulation 2002 ; 105 : 2139-2142
 
22) Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis : a randomized controlled trial. JAMA 2003 ; 290 : 238-247.
PubMed
23) Nordfang O, Valentin S, Beck TC, et al. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991 ; 66 : 464-467.
PubMed
24) Maroney SA, Cooley BC, Ferrel JP, et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 2012 ; 109 : 3927-3931.
PubMed
25) Waters EK, Genga RM, Schwartz MC, et al. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011 ; 117 : 5514-5522
 
26) Vincent LM, Tran S, Livaja R, et al : Coagulation factor V (A2440G) causes east Texas bleeding disorder via TFPIα . J Clin Invest 2013 ; 123 : 3777-3787.
 
27) Nakamura Y, Nakamura K, Ohta K. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. Basic Res Cardiol 2002 ; 97 : 198-205.
PubMed
28) Kopp CW, Holzenbein T, Steiner S, et al : Inhibition of restenosis by tissue factor pathway inhibitor : in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity. Blood 2004 ; 103 : 1653-1661.
PubMed
29) Chand HS, Du X, Ma D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004 ; 103 : 1069-1077.
PubMed
P.48 掲載の参考文献
1) Fujimaki K, Yamazaki T, Taniwaki M, et al. The gene for human protein Z is located to chromosome 13 at band q34 and is coded by eight regular exons and one alternative exon. Biochemistry 1998 ; 37 : 6838-6846.
 
2) Ichinose A, Takeya H, Espling E, et al. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun 1990 ; 172 : 1139-1144.
PubMed
3) Sejima H, Hayashi T, Deyashiki Y, et al. Primary structure of vitamin K-dependent human protein Z. Biochem Biophys Res Commun 1990 ; 171 : 661-668.
PubMed
4) Nishijima H, Kawabata S, Kisiel W, et al. Identification of a disaccharide (Xyl-Glc) and a trisaccharide (Xyl2-Glc) O-glycosidically linked to a serine in the first epidermal growth factor-like domain of human factors VII and IX and protein Z and bovine protein Z. J Biol Chem 1989 ; 264 : 20320-20325.
 
5) Han X, Huang ZF, Fiehler R, et al. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999 ; 38 : 11073-11078.
PubMed
6) Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000 ; 96 : 3049-3055.
PubMed
7) Tabatabai A, Fiehler R, Broze GJ Jr. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor. Thromb Haemost 2001 ; 85 : 655-660.
 
8) Rezaie AR, Bae J, Manithody C, et al. Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem 2008 ; 283 : 19922-19926.
 
9) Wei Z, Yan Y, Carrell RW, et al. Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X. Blood 2009 ; 114 : 3662-3667.
 
10) Huang X, Yan Y, Tu Y, et al. Structural basis for catalytic activation of protein Z-dependent protease inhibitor (ZPI) by protein Z. Blood 2012 ; 120 : 1726-1733.
 
11) Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci USA. 1998 ; 95 : 9250-9255.
PubMed
12) Huang X, Swanson R, Broze GJ Jr, et al. Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa. J Biol Chem 2008 ; 283 : 29770-29783.
 
13) Huang X, Rezaie AR, Broze GJ Jr, et al. Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor. J Biol Chem 2011 ; 286 : 8740-8751.
 
14) Sugawara H, Iwata H, Souri M, et al. Regulation of human protein Z gene expression by liver-enriched transcription factor HNF-4α and ubiquitous factor Sp1. J Thromb Haemost 2007 ; 5 : 2250-2258.
 
15) Vasse M, Denoyelle C, Corbiere C, et al. Human endothelial cells synthesize protein Z, but not the protein Z-dependent inhibitor. Thromb Haemost 2006 ; 95 : 519-523.
 
16) Capurso G, Lattimore S, Crnogorac-Jurcevic T, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006 ; 13 : 541-558.
PubMed
17) Leja J, Essaghir A, Essand M, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mol Pathol 2009 ; 22 : 261-272.
 
18) Sierko E, Wojtukiewicz MZ, Ostrowska-Cichocka K, et al. Protein Z-dependent protease inhibitor (ZPI) is present in loco in human breast cancer tissue. Thromb Haemost 2010 ; 104 : 183-185.
PubMed
19) Sierko E, Wojtukiewicz MZ, Zimnoch L, et al. Protein Z is present in human breast cancer tissue. Int J Hematol 2011 ; 93 : 681-683.
PubMed
20) Miletich JP, Broze GJ Jr. Human plasma protein Z antigen : range in normal subjects and effect of warfarin therapy. Blood 1987 ; 69 : 1580-1586.
PubMed
21) Souri M, Sugiura-Ogasawara M, Saito S, et al. Increase in the plasma levels of protein Z-dependent protease inhibitor in normal pregnancies but not in non-pregnant patients with unexplained recurrent miscarriage. Thromb Haemost 2012 ; 107 : 507-512.
 
22) Souri M, Iwata H, Zhang WG, et al. Unique secretion mode of human protein Z : its Gla domain is responsible for inefficient, vitamin K-dependent and warfarinsensitive secretion. Blood 2009 ; 113 : 3857-3864.
PubMed
23) Vossen CY, Hasstedt SJ, Rosendaal FR, et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004 ; 2 : 242-247.
 
24) Santacroce R, Cappucci F, Di Perna P, et al. Protein Z gene polymorphisms are associated with protein Z plasma levels. J Thromb Haemost 2004 ; 2 : 1197-1199.
 
25) Lichy C, Kropp S, Dong-Si T, et al. A common polymorphism of the protein Z gene is associated with protein Z plasma levels and with risk of cerebral ischemia in the young. Stroke 2004 ; 35 : 40-45.
 
26) Souri M, Koseki-Kuno S, Iwata H, et al. A naturally occurring E30Q mutation in the Gla domain of protein Z causes its impaired secretion and subsequent deficiency. Blood 2005 ; 105 : 3149-3154.
PubMed
27) Iwata H, Souri M, Kemkes-Matthes B, et al. An additional Glu30Lys substitution in the Gla domain of the protein Z gene is not a common polymorphism but rare mutation. J Thromb Haemost 2005 ; 3 : 2360-2361.
 
28) Van de Water N, Tan T, Ashton F, et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease : a new form of thrombophilia. Br J Haematol 2004 ; 127 : 190-194.
PubMed
29) Corral J, Gonzalez-Conejero R, Soria JM, et al. A nonsense polymorphism in protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 2006 ; 108 : 177-183.
PubMed
30) Young LK, Birch NP, Browett PJ, et al. Two missense mutations identified in venous thrombosis patients impair the inhibitory function of the protein Z dependent protease inhibitor. Thromb Haemost. 2012 ; 107 : 854-863.
PubMed
31) Yin Z-F, Huang Z-F, Cui J, et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci USA 2000 ; 97 : 6734-6738.
PubMed
32) Zhang J, Tu Y, Lu L, et al. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deificiency. Blood 2008 ; 111 : 4973-4978.
 
33) Vasse M, Guegan-Massardier E, Borg JY, et al. Frequency of protein Z deficiency in patients with ischemic stroke. Lancet 2001 ; 357 : 933-934.
 
34) Al-Shanqeeti A, van Hylckama Vlieg A, Berntorp E, et al. Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis. Thromb Haemost 2005 ; 93 : 411-413.
PubMed
35) Martinelli I, Razzari C, Biguzzi E, et al. Low levels of protein Z and the risk of venous thromboembolism. J Thromb Haemost 2005 ; 3 : 2817-2819.
PubMed
36) Santacroce R, Sarno M, Cappucci F, et al. Low protein Z levelsand risk of occurrence of deep vein thrombosis. J Thromb Haemost 2006 ; 4 : 2417-2422.
 
37) Pardos-Gea J, Ordi-Ros J, Serrano S, et al. Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. Thromb Res 2008 ; 121 : 727-734.
PubMed
38) Kemkes-Matthes B, Nees M, Kuhnel G, et al. Protein Z influences the prothrombotic phenotype in factor V Leiden patients. Thromb Res 2002 ; 106 : 183-185.
PubMed
39) Kobelt K, Biasiutti FD, Mattle HP, et al. Protein Z in ischemic stroke. Br J Haematol. 2001 ; 114 ; 169-173.
 
40) Lopaciuk S, Bykowska K, Kwiecinski H, et al. Protein Z in young survivors of ischemic stroke. Thromb Haemost. 2002 ; 88 : 536.
PubMed
41) McQuillan AM, Eikelboom JW, Hankey GJ, et al. Protein Z in ischemic stroke and its etiologic subtypes. Stroke 2003 ; 34 : 2415-2419.
PubMed
42) Vasse M. Protein Z, a protein seeking a pathology. Thromb Haemost 2008 ; 100 : 548-556.
PubMed
43) Sofi F, Cesari F, Tu Y, et al. Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost 2009 ; 7 : 731-735.
PubMed
44) Quack Loetscher KC, Stiller R, Roos M, et al. Protein Z in normal pregnancy. Thromb Haemost 2005 ; 93 : 706-709.
PubMed

2部 線溶反応

P.64 掲載の参考文献
1) Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003 ; 89 : 409-419.
PubMed
2) Miles LA, Parmer RJ. Plasminogen receptors : the first quarter century. Semin Thromb Hemost 2013 ; 39 : 329-337.
PubMed
3) Andronicos NM, Chen EI, Baik N, et al. Proteomicsbased discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 2010 ; 115 : 1319-1330.
 
4) Miles LA, Lighvani S, Baik N, et al. New insights into the role of Plg-RKT in macrophage recruitment. Int Rev Cell Mol Biol 2014 ; 309 : 259-302.
PubMed
5) Han J, Baik N, Kim KH, et al. Monoclonal antibodies detect receptor-induced binding sites in Gluplasminogen. Blood 2011 ; 118 : 1653-1662.
PubMed
6) Draxler DF, Medcalf RL. The fibrinolytic system-more than fibrinolysis? Transfus Med Rev 2015 ; 29 : 102-109.
PubMed
7) Parcq J, Bertrand T, Montagne A, et al. Unveiling an exceptional zymogen : the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ 2012 ; 19 : 1983-1991.
 
8) Velnar T, Bailey T, Smrkolj V. The wound healing process : an overview of the cellular and molecular mechanisms. J Int Med Res 2009 ; 37 : 1528-1542.
PubMed
9) Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005 ; 93 : 647-654.
PubMed
10) Ariens RA. Fibrin (ogen) and thrombotic disease. J Thromb Haemost 2013 ; 11 (Suppl 1) : 294-305.
 
11) Kasahara K, Kaneda M, Miki T, et al. Clot retraction is mediated by factor XIII-dependent fibrin-α IIbβ 3-myosin axis in platelet sphingomyelin-rich membrane rafts. Blood 2013 ; 122 : 3340-3348.
 
12) Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992 ; 79 : 1420-1427.
PubMed
13) Aleman MM, Byrnes JR, Wang JG, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. J Clin Invest 2014 ; 124 : 3590-3600.
PubMed
14) Blinc A, Keber D, Lahajnar G, et al. Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro. Haemostasis. 1992 ; 22 : 195-201.
PubMed
15) Wohner N, Sotonyi P, Machovich R, et al. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb Vasc Biol 2011 ; 31 : 2306-2313.
PubMed
16) Foley JH, Peterson EA, Lei V, et al. Interplay between fibrinolysis and complement : plasmin cleavage of iC3b modulates immune responses. J Thromb Haemost 2015 ; 13 : 610-618.
PubMed
17) Howes JM, Richardson VR, Smith KA, et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012 ; 9 : 216-25.
PubMed
18) Carmeliet P1, Moons L, Dewerchin M, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann N Y Acad Sci. 1997 ; 811 : 191-206.
 
19) Law RH, Caradoc-Davies T, Cowieson N, et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012 ; 1 : 185-190.
PubMed
20) 段孝, 宮田敏男. PAI-1阻害薬・そのポテンシャルと臨床への応用. 日本血栓止血学会誌. 2015 ; 26 : 310-317.
 
21) Souri M, Osaki T, Ichinose A. The Non-catalytic B Subunit of Coagulation Factor XIII Accelerates Fibrin Cross-linking. J Biol Chem 2015 ; 290 : 12027-12039.
PubMed
22) Jaffer FA, Tung CH, Wykrzykowska JJ, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation 2004 ; 110 : 170-176.
PubMed
23) Noguchi K, Edo N, Ito Y, et al. DS-1040 : a novel selective inhibitor of activated form of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2015 ; 13 (Suppl 2) : 336 (Abstracts PO203-MON).
 
24) Bhattacharya S, Ploplis VA, Castellino FJ. Bacterial plasminogen receptors utilize host plasminogen system for effective invasion and dissemination. J Biomed Biotechnol 2012 ; 2012 : 482096.
PubMed
25) 早川佳奈, 田村志宣, 義間大也, 他. 遺伝子組換えトロンボモジュリン製剤が奏効した維持透析中の解離性大動脈瘤に合併した慢性播種性血管内凝固. 臨床血液 2014 ; 55 : 2300-2305.
 
26) Cap A, Hunt BJ. The pathogenesis of traumatic coagulopathy. Anaesthesia 2015 ; 70 (Suppl 1) : 96-101, e32-e34.
 
27) Lucassen WA, Erkens PM, Geersing GJ, et al. Qualitative point-of-care D-dimer testing compared with quantitative D-dimer testing in excluding pulmonary embolism in primary care. J Thromb Haemost 2015 ; 13 : 1004-1009.
PubMed
28) Madoiwa S, Kitajima I, Ohmori T, et al. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. Thromb Res 2013 ; 132 : 457-464.
 
29) 一瀬白帝. 後天性凝固異常症のP.O.C. テストによる迅速診断システムの開発に関する研究. 厚生労働科学研究委託費 難治性疾患実用化研究事業 平成26年度委託業務成果報告書. 2015.
 
30) CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) : a randomised, placebo-controlled trial. Lancet 2010 ; 376 : 23-32.
PubMed
31) Godier A, Roberts I, Hunt BJ. Tranexamic acid : less bleeding and less thrombosis? Crit Care 2012 ; 16 : 135.
PubMed
32) Tengborn L, Blomback M, Berntorp E. Tranexamic acid--an old drug still going strong and making a revival. Thromb Res 2015 ; 135 : 231-242.
PubMed
33) Miyaji Y, Yoshimura S, Sakai N, et al. Effect of edaravone on favorable outcome in patients with acute cerebral large vessel occlusion : subanalysis of RESCUE-Japan Registry. Neurol Med Chir (Tokyo) 2015 ; 55 : 241-247.
PubMed
34) 阿部康二. 脳梗塞急性期治療のtherapeutic time window. 臨床神経学 2011 ; 51 : 1182-1184.
 
35) Engesser L, Brommer EJ, Kluft C, et al. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemost 1989 ; 62 : 673-680.
PubMed
36) Lau HK, Teitel JM, Cheung T, et al. Hypofibrinolysis in patients with hypercoagulability : the roles of urokinase and of plasminogen activator inhibitor. Am J Hematol 1993 ; 44 : 260-265.
PubMed
37) Glueck CJ, Munjal J, Aregawi D, et al. Thrombophiliahypofibrinolysis and atherothrombotic cardiovascular disease < or = age 45 years. Transl Res 2007 ; 150 : 93-100.
PubMed
38) Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010 ; 116 : 113-121.
PubMed
39) Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem 2012 ; 287 : 18831-18842.
PubMed
40) Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014 ; 25 : 55-64.
PubMed
P.73 掲載の参考文献
1) Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physio Rev 1993 ; 73 : 161-195.
 
2) Tefs K, Gueorguieva M, Klammt J, et al. Molecular and clinical spectrum of type I plasminogen deficiency : a series of 50 patients. Blood 2006 ; 108 : 3021-3026.
PubMed
3) Okamoto A, Sakata T, Mannami T, et al. Populationbased distribution of plasminogen activity and estimated prevalence and relevance to thrombotic diseases of plasminogen deficiency in the Japanese : the Suita Study. J Thromb Haemost 2003 ; 1 : 2397-2403.
PubMed
4) Castellino FJ and Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005 ; 93 : 647-654.
PubMed
5) Schuster V, Hugle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007 ; 5 : 2315-2322.
PubMed
6) Petersen TE, Martzen MR, Ichinose A, et al. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 1990 ; 265 : 6104-6111.
PubMed
7) Suzuki T, Ikewaki J, Iwata H, et al. The first two Japanese cases of severe type I congenital plasminogen deficiency with ligneous conjunctivitis : successful treatment with direct thrombin inhibitor and fresh plasma. Am J Hematol 2009 ; 84 : 363-365.
PubMed
8) Bugge TH, Flick MJ, Daugherty CC, et al. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995 ; 9 : 794-807.
PubMed
9) Ploplis VA, Carmeliet P, Vazirzadeh S, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995 ; 92 : 2585-2593.
PubMed
10) Aoki N, Moroi M, Sakata Y, et al. Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978 ; 61 : 1186-1195.
 
11) Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia 2008 ; 14 : 1261-1268.
PubMed
12) Klammt J, Kobelt L, Aktas D, et al. Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. Thromb Haemost 2011 ; 105 : 454-460.
 
13) Drew AF, Kaufman AH, Kombrinck KW, et al. Ligneous conjunctivitis in plsminogen-deficient mice. Blood 1998 ; 91 : 1616-1624.
 
14) Bugge TH, Kombrinck KW, Flick MJ, et al. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996 ; 87 : 709-719.
PubMed
15) Fay WP, Garg N and Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007 ; 27 : 1231-1237.
PubMed
16) Deryugina EI and Quigley JP. Cell surface remodeling by plasmin : a new function for an old enzyme. J Biomed Biotechnol 2012 ; 564259 : 1-21.
 
17) Das R, Pluskota E, Plow EF. Plasminogen and its receptors as regulators of cardiovascular inflammatory responses. Trends Cardiovasc Med 2010 ; 20 : 120-124.
PubMed
18) Sun H. The interaction between pathogens and the host coagulation system. Physiology 2006 ; 21 : 281-288.
PubMed
19) Fulde M, Steinert M, Bergmann S. Interaction of streptococcal plasminogen binding proteins with the host fibrinolytic system. Front Cell Infect Microbiol 2013 ; 3 : 85.
PubMed
20) Murray V, Norrving B, Sandercock PA, et al. The molecular basis of thrombolysis and its clinical application in stroke. J Intern Med 2010 ; 267 : 191-208.
PubMed
21) Hasumi K, Yamamichi S, Harada T. Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems. FEBS J 2010 ; 277 : 3675-3687.
PubMed
22) Miyashita C, Wenzel E, Heiden M. Plasminogen : a brief introduction into its biochemistry and function. Haemostasis 1988 ; 18 Suppl 1 : 7-13.
 
23) Law RH, Caradoc-Davies T, Cowieson N, et al. The X-ray crystal structure of full-length human plasminogen. Cell Rep 2012 ; 1 : 185-190.
PubMed
24) Xue Y, Bodin C, Olsson K. Crystal structure of the native plasminogen reveals an activation-resistant compact conformation. J Thromb Haemost 2012 ; 10 : 1385-1396.
PubMed
25) Horrevoets AJG, Smilde AE, Fredenburgh JC, et al. The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge region. J Biol Chem 1995 ; 270 : 15770-15776.
 
26) Ho-Tin-Noe B, Rojas G, Vranckx R, et al. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. FEBS J 2005 ; 272 : 3387-3400.
PubMed
27) Ichinose A, Fujikawa K and Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Bio Chem 1985 ; 261 : 3486-3489.
 
28) Gong Y, Kim SO, Felez J, et al. Conversion of Gluplasminogen to Lys-plasminogen is necessary for optimal stimulation of plasminogen activation on the endothelial cell surface. J Biol Chem 2001 ; 276 : 19078-19083.
 
29) Plow EF, Herren T, Redlitz A, et al. The cell biology of the plasminogen system. FASEB J 1995 ; 9 : 939-945.
PubMed
30) Dobrovolsky AB, Titaeva EV. The fibrinolysis system : regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 2002 ; 67 : 99-108.
PubMed
31) Kwaan HC. From fibrinolysis to the plasminogen-plasmin system and beyond : A remarkable growth of knowledge, with personal observations on the history of fibrinolysis. Semin Thromb Hemost 2014 ; 40 : 585-591.
 
32) Law RH, Abu-Ssaydeh D, Whisstock JC. New insights into the structure and function of the plasminogen/plasmin system. Curr Opin Struct Biol 2014 ; 23 : 836-841.
 
33) 尾崎司, 一瀬白帝. 線溶系の異常. In : 一瀬白帝, 鈴木宏治編. 図説分子病態学. 改訂5版. 東京 : 中外医学社, 2014 : 221-226.
 
P.80 掲載の参考文献
1) Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2008 ; 7 : 4-13.
PubMed
2) 岡田清孝, 松尾理. 線溶系因子ノックアウトマウスと細胞性線溶. In : 坂田洋一, 小澤敬也編. 別冊・医学のあゆみ血液疾患-State of arts. 東京 : 医歯薬出版, 2005 : 343-348.
 
3) Ellis V, Dano K. u-Plasminogen activator. In : Barrett AJ, Rawlings ND, Woessner JF, editors. Handbook of Proteolytic Enzymes. San Diego : Academic Press, 1998 : 177-184.
 
4) Finckh U, van Hadeln K, Muller-Thomsen T, et al. Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2. Neurogenetics 2003 ; 4 : 213-217.
PubMed
5) Bando H, Okada K, Matsuo O. Thrombolytic effect of pro-urokinase in vitro. Fibrinolysis 1987 ; 1 : 169-176.
 
6) Besser D, Verde R, Nagamine Y, et al. Signal transduction and the u-PA/u-PAR system. Fibrinolysis 1996 ; 10 : 215-237.
 
7) De Cesare D, Palazzolo M, Berthelsen J. Characterization of UEF-4, a DNA-binding protein required for transcriptional synergism between two AP-1 sites in the human urokinase enhancer. J Biol Chem 1997 ; 272 : 23921-23929.
PubMed
8) King RH, Rabbani SA. Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells : role of DNA methylation. Int J Cancer 1999 ; 81 : 443-450.
 
9) Kaht WH, Zheng S, sheth PM, et al. Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator. Blood 2001 ; 98 : 257-265.
 
10) Carmeliet P, Schoonjans L, Kieckens L, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994 ; 368 : 419-424.
PubMed
11) Wu F, Catano M, Echeverry R, et al. Urokinase-type plasminogen activator promotes dendritic spine recovery and improves neurological outcome following ischemic stroke. J Neurosci 2014 ; 34 : 14219-14232.
PubMed
12) Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene : correlation of intron and exson structures to functional and structural domains. Proc Natl Acad Sci USA 1984 ; 81 : 5355-5359.
 
13) Biessen EA, van Teijingen M, Vietsch H, et al. Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation 1997 ; 95 : 46-52.
 
14) Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981 ; 291 : 590-591.
PubMed
15) Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982 : 257 : 2912-2919.
PubMed
16) Ichinose A, Takio K, Fujikawa K. Localization of the binding site of tissue-type plasminogen activator to fibrin. J Clin Invest 1986 ; 78 : 163-169.
PubMed
17) Kooistra T, Schrauwen Y, Arts J, et al. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994 ; 59 : 233-255.
PubMed
18) Madison EL, Gokldsmith EJ, Gerard RD, et al. Serpinresistant mutants of human tissue-type plasminogen activator. Nature 1989 ; 339 : 721-724.
 
19) Qian Z, Gilbert ME, Colicos MA, et al. Tissue-type plasminogen activator is induced as an immediateearly gene during seizure, kindling and long-term potentiation. Nature 1993 ; 361 : 453-457.
PubMed
20) Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997 ; 91 : 917-925.
PubMed
21) Uhl B, Zuchtriegel G, Puhr-Westerheide D, et al. Tissue plasminogen activator promotes postischemic neutrophil recruitment via its proteolytic and nonproteolytic properties. Arterioscler Thromb Vasc Biol 2014 ; 34 : 1495-1504.
PubMed
22) Kawao N, Tamura Y, Okumoto K, et al. Plasminogen plays a crucial role in bone repair. J Bone Miner Res 2013 ; 28 : 1561-1574.
 
23) Novakovic R, Toth G, Purdy PD. Review of current and emerging therapies in acute ischemic stroke. J Neurolntery Surg 2009 ; 1 : 13-26.
PubMed
24) Nordt TK, Bode C. Thrombolysis : newer thrombolytic agents and their role in clinical medicine. Heart 2003 ; 89 : 1358-1362.
PubMed
25) Meyer G, Vicaut E, Danays T, et al. PEITHO Investigators : Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014 ; 370 : 1402-1411.
PubMed
26) Niego B, Medcalf RL. Plasmin-dependent modulation of the blood-brain barrier : a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab 2014 ; 34 : 1283-1296.
 
27) Reddy KN. Streptokinase-biochemistry and clinical application. Enzyme. 1988 ; 40 : 79-89.
PubMed
28) Mundada LV, Prorok M, DeFord ME, et al. Structurefunction analysis of streptokinase amino terminus (residues 1-59). J Biol Chem 2003 ; 278 : 24421-24427.
PubMed
29) Wu DH, Shi GY, Chuang WJ, et al. Coiled coil region of streptokinase g-domain is essential for plasminogen activation. J Biol Chem 2001 ; 276 : 15025-15033.
 
30) Lack CH. Staphylokinase : an activation of plasma protease. Nature 1948 ; 161 : 559-560.
PubMed
31) Okada K, Ueshima S, Takaishi T, et al. Effects of fibrin and a2-antiplasmin on plasminogen activation by staphylokinase. Am J Hemat 1996 ; 53 : 151-157.
 
32) Matsuo O, Okada K, Fukao H, et al. Thromblytic properties of staphylokinase. Blood 1990 ; 76 : 925-929.
 
33) Collen D, Sinnaeve P, Demarsin E, et al. Polyethylene glycol-derivatized cysteine-substitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation 2000 ; 102 : 1766-1772.
PubMed
34) Bringmann P, Gruber D, Liese A, et al. Structural features mediating fibrin selectivity of Vampire bat plasminogen activators. J Biol Chem 1995 ; 270 : 25596-25603.
PubMed
35) Medcalf RL. Desmoteplase : discovery, insights and opportunities for ischaemic stroke. Brit J Pharmaco 2012 ; 165 : 75-89.
 
36) Freeman R, Niego B, Croucher DR, et al. t-PA, but not desmoteplase, induces plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions. Brain Res 2014 ; 1565 : 63-73.
 
37) Ploug M, Gardsvoll H, Jorgensen TJ, et al. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor : a potential target for anti-invasive cancer therapy. Biochem Soc Trans 2002 ; 30 : 177-183.
PubMed
38) Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997 ; 15 : 398-408.
PubMed
39) Bifulco K, Longanesi-Cattani I, Gala M, et al. The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence. J Thromb Haemost 2010 ; 8 : 2789-2799.
PubMed
40) Haupt TH, Kallemose T, Ladelund S, et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomarker Insights 2014 ; 9 : 91-100.
 
41) Ishida C, Ueshima S, Nagai N, et al. Enhancement of fibrinolytic activity in vascular endothelial cells by heterologous expression of adenine nucleotide translocase-1. Blood Coagul Fibrino 2008 ; 21 : 272-278.
 
42) Madureira PA, Surette AP, Phipps KD, et al. The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood 2011 ; 118 : 4789-4797.
PubMed
43) Kruithof EKO, Dunoyer-Geinder S. Human tissue-type plasminogen activator. Thromb Haemost 2014 ; 112 : 243-254.
 
P.88 掲載の参考文献
1) Knipe L, Meli A, Hewlett L, et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood 2010 ; 116 : 2183-2191.
PubMed
2) Datta YH, Youssoufian H, Marks PW, et al. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells. Blood 1999 ; 94 : 2696-2703.
PubMed
3) Huber D, Cramer EM, Kaufmann JE, et al. Tissuetype plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo. Blood 2002 ; 99 : 3637-3645.
PubMed
4) Suzuki Y, Mogami H, Ihara H, et al. Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 2009 ; 113 : 470-478.
PubMed
5) Urano T, deSerrano VS, Urano S, et al. Stimulat ion by fibrinogen of the amidolytic activity of single-chain tissue plasminogen activator. Arch Biochem Biophys 1989 ; 270 : 356-362.
 
6) Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J Thromb Haemost 2007 ; 5 : 804-811.
PubMed
7) 鈴木優子. 血管内皮細胞におけるtPAの独特な分泌動態とPAI-1による修飾. 血栓止誌 2009 ; 20 : 428-436.
 
8) Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997 ; 78 : 656-660.
PubMed
9) Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women : evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998 ; 98 : 2241-2247.
PubMed
10) Taraska JW, Almers W. Bilayers merge even when exocytosis is transient. Proc Natl Acad Sci USA 2004 ; 101 : 8780-8785.
PubMed
11) Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994 ; 91 (9) : 3670-3674.
PubMed
12) 鈴木優子, 佐野秀人, Brzoska Tomasz, 他. リアルタイムイメージングによる修飾tPAの分泌動態. 血栓止血誌, 2014 ; 25 : 259.
 
13) Kranenburg O, Bouma B, Kroon-Batenburg LM, et al. Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr Biol 2002 ; 12 : 1833-1839.
PubMed
14) Roda O, Chiva C, Espuna G, et al. A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells. Proteomics 2006 ; 6 (Suppl 1) : S36-41.
 
15) Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999 ; 340 : 994-1004.
PubMed
16) Ling Q, Jacovina AT, Deora A, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004 ; 113 : 38-48.
PubMed
17) Samson AL, Borg RJ, Niego B, et al. A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury. Blood 2009 ; 114 : 1937-1946.
PubMed
18) Suzuki Y, Yasui H, Brzoska T et al. Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. Blood 2011 ; 118 : 3182-3185.
PubMed
19) 鈴木優子, 佐野秀人, Martyna Tomczyk他. 血管内皮細胞発現tPA によるプラスミン産生ならびに線溶能の定量評価と変異型tPAの機能解析. 血栓止血誌 2015 ; 26 : 197.
 
20) Parsons M, Spratt N, Bivard A et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012 ; 366 : 1099-1107.
PubMed
21) Coutts SB, Dubuc V, Mandzia J et al. Tenecteplasetissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke ; 2015 ; 46 : 769-774.
 
22) Yepes M, Roussel BD, Ali C, et al. Tissue-type plasminogen activator in the ischemic brain : more than a thrombolytic. Trends Neurosci 2009 ; 32 : 48-55.
PubMed
23) Niego B, Freeman R, Puschmann TB et al. t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 2012 ; 119 : 4752-4761.
PubMed
24) Niego B, Medcalf RL. Plasmin-dependent modulation of the blood-brain barrier : a major consideration during tPA-induced thrombolysis? J Cereb Blood Flow Metab 2014 ; 34 : 1283-1296.
 
P.94 掲載の参考文献
1) Kato A, Hirosawa S, Toyota S, et al. Localization of the human alpha 2-plasmin inhibitor gene (PLI) to 17p13. Cytogenet Cell Genet 1993 ; 62 : 190-191.
PubMed
2) Hirosawa S, Nakamura Y, Miura O, et al. Organization of the human alpha 2-plasmin inhibitor gene. Proc Natl Acad Sci USA 1988 ; 85 : 6836-6840.
PubMed
3) Miura O, Sugahara Y, Nakamura Y, et al. Restriction fragment length polymorphism caused by a deletion involving Alu sequences within the human alpha 2-plasmin inhibitor gene. Biochemistry 1989 ; 28 : 4934-4938.
PubMed
4) Holmes WE, Nelles L, Lijnen HR, et al. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987 ; 262 : 1659-1664.
PubMed
5) Aoki N, Harpel PC. Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 1984 ; 10 : 24-41.
PubMed
6) Bangert K, Johnsen AH, Christensen U, et al. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 1993 ; 291 (Pt 2) : 623-625.
 
7) Koyama T, Koike Y, Toyota S, et al. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994 ; 200 : 417-422.
PubMed
8) Lee KN, Jackson KW, Christiansen VJ, et al. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004 ; 103 : 3783-3788.
PubMed
9) Lee KN, Jackson KW, Christiansen VJ, et al. Alpha2-antiplasmin : potential therapeutic roles in fibrin survival and removal. Curr Med Chem Cardiovasc Hematol Agents 2004 ; 2 : 303-310.
PubMed
10) Kluft C, Los P, Jie AF, et al. The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. Blood 1986 ; 67 : 616-622.
PubMed
11) Sasaki T, Morita T, Iwanaga S. Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor. J Biochem 1986 ; 99 : 1699-1705.
PubMed
12) Menoud PA, Sappino N, Boudal-Khoshbeen M, et al. The kidney is a major site of alpha (2) -antiplasmin production. J Clin Invest 1996 ; 97 : 2478-2484.
 
13) Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978 ; 84 : 573-578.
PubMed
14) Lee KN, Lee CS, Tae WC, et al. Cross-linking of wildtype and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000 ; 275 : 37382-37389.
PubMed
15) Sumi Y, Ichikawa Y, Nakamura Y, et al. Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem 1989 ; 106 : 703-707.
PubMed
16) Nieuwenhuizen L, Roosendaal G, Mastbergen SC,et al. Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. J Thromb Haemost 2014 ; 12 : 237-245.
 
17) Lijnen HR, Okada K, Matsuo O, et al. Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999 ; 93 : 2274-2281.
PubMed
18) Takei M, Matsuno H, Okada K, et al. Lack of alpha 2-antiplasmin enhances ADP induced platelet microaggregation through the presence of excess active plasmin in mice. J Thromb Thrombolysis 2002 ; 14 : 205-211.
PubMed
19) Kawashita E, Kanno Y, Ikeda K, et al. Altered behavior in mice with deletion of the alpha2-antiplasmin gene. PLoS One 2014 ; 9 : e97947.
PubMed
20) Nagai N, De Mol M, Lijnen HR, et al. Role of plasminogen system components in focal cerebral ischemic infarction : a gene targeting and gene transfer study in mice. Circulation 1999 ; 99 : 2440-2444.
PubMed
21) Matsuno H, Kozawa O, Okada K, et al. Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice. J Cardiovasc Pharmacol 2002 ; 39 : 278-286.
PubMed
22) Matsuno H, Kozawa O, Okada K, et al. Plasmin generation plays different roles in the formation and removal of arterial and venous thrombus in mice. Thromb Haemost 2002 ; 87 : 98-104.
PubMed
23) Reed GL, Houng AK, Wang D. Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating alpha2-antiplasmin. Arterioscler Thromb Vasc Biol 2014 ; 34 : 2586-2593.
PubMed
24) Hou Y, Okada K, Okamoto C, et al Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling. Arterioscler Thromb Vasc Biol 2008 ; 28 : 1257-1262.
PubMed
25) Matsuno H, Ishisaki A, Nakajima K, et al. Lack of alpha 2-antiplasmin promotes re-endothelialization via over-release of VEGF after vascular injury in mice. Blood 2003 ; 102 : 3621-3628.
PubMed
26) Kanno Y, Hirade K, Ishisaki A, et al. Lack of alpha2-antiplasmin improves cutaneous wound healing via over-released vascular endothelial growth factorinduced angiogenesis in wound lesions. J Thromb Haemost 2006 ; 4 : 1602-1610.
PubMed
27) Matsuno H, Kozawa O, Yoshimi N,et al. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002 ; 100 : 2487-2493.
PubMed
28) Kitching AR, Turner AL, O'Sullivan KM, et al. Endogenous alpha2-antiplasmin does not enhance glomerular fibrin deposition or injury in glomerulonephritis. J Thromb Haemost 2003 ; 1 : 1992-1999.
PubMed
29) Kager LM, Weehuizen TA, Wiersinga WJ, et al. Endogenous alpha2-antiplasmin is protective during severe gram-negative sepsis (melioidosis). Am J Respir Crit Care Med 2013 ; 188 : 967-975.
PubMed
30) Kanno Y, Kawashita E, Minamida M, et al. alpha2-antiplasmin is associated with the progression of fibrosis. Am J Pathol 2010 ; 176 : 238-245.
PubMed
31) Kanno Y, Kawashita E, Kokado A,et al. Alpha2-antiplasmin regulates the development of dermal fibrosis in mice by prostaglandin F (2alpha) synthesis through adipose triglyceride lipase/calcium-independent ospholipase A (2). Arthritis Rheum 2013 ; 65 : 492-502.
 
32) Shiomi A, Kawao N, Yano M, et al. alpha2-Antiplasmin is involved in bone loss induced by ovariectomy in mice. Bone 2015 ; 79 : 233-241.
PubMed
33) Okada K, Ueshima S, Kawao N, et al. Lack of both alpha2-antiplasmin and plasminogen activator inhibitor type-1 induces high IgE production. Life Sci 2013 ; 93 : 89-95.
PubMed
34) Miura O, Hirosawa S, Kato A, et al. Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest 1989 ; 83 : 1598-1604.
PubMed
35) Miura O, Sugahara Y, Aoki N. Hereditary alpha 2-plasmin inhibitor deficiency caused by a transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. J Biol Chem 1989 ; 264 : 18213-18219.
PubMed
36) Holmes WE, Lijnen HR, Nelles L,et al. Alpha 2-antiplasmin Enschede : alanine insertion and abolition of plasmin inhibitory activity. Science 1987 ; 238 : 209-211.
PubMed
37) Hennis BC, Frants RR, Bakker E, et al. Evidence for the absence of intron H of the histidine-rich glycoprotein (HRG) gene : genetic mapping and in situ localization of HRG to chromosome 3q28-q29. Genomics 1994 ; 19 : 195-197.
 
38) Wakabayashi S, Takahashi K, Koide T. Structural characterization of the gene for human histidine-rich glycoprotein, reinvestigation of the 5'-terminal region of cDNA and a search for the liver specific promoter in the gene. J Biochem 1999 ; 125 : 522-530.
 
39) Koide T, Foster D, Yoshitake S, et al. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 1986 ; 25 : 2220-2225.
PubMed
40) Morgan WT, Koskelo P, Koenig H, et al. Human histidine-rich glycoprotein. II. Serum levels in adults, pregnant women and neonates. Proc Soc Exp Biol Med 1978 ; 158 : 647-651.
PubMed
41) Lijnen HR, Jacobs G, Collen D. Histidine-rich glycoprotein in a normal and a clinical population. Thromb Res 1981 ; 22 : 519-523.
 
42) Leebeek FW, Kluft C, Knot EA, et al. Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis. J Lab Clin Med 1989 ; 113 : 493-497.
PubMed
43) Leung LL, Harpel PC, Nachman RL, et al. Histidinerich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983 ; 62 : 1016-1021.
PubMed
44) Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986 ; 77 : 1305-1311.
PubMed
45) Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980 ; 255 : 10214-10222.
PubMed
46) Silverstein RL, Nachman RL, Leung LL, et al. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem 1985 ; 260 : 10346-10352.
PubMed
47) Poon IK, Patel KK, Davis DS, et al. Histidine-rich glycoprotein : the Swiss Army knife of mammalian plasma. Blood 2011 ; 117 : 2093-2101.
PubMed
48) Tsuchida-Straeten N, Ensslen S, Schafer C, et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 2005 ; 3 : 865-872.
PubMed
49) Simantov R, Febbraio M, Crombie R, et al. Histidinerich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest 2001 ; 107 : 45-52.
PubMed
50) Rydengard V, Olsson AK, Morgelin M, et al. Histidinerich glycoprotein exerts antibacterial activity. FEBS J 2007 ; 274 : 377-389.
PubMed
51) Silverstein RL, Febbraio M. CD36-TSP-HRGP interactions in the regulation of angiogenesis. Curr Pharm Des 2007 ; 13 : 3559-3567.
PubMed
52) Shigekiyo T, Ohshima T, Oka H, et al. Congenital histidine-rich glycoprotein deficiency. Thromb Haemost 1993 ; 70 : 263-5.
PubMed
53) Souto JC, Gari M, Falkon L, et al. A new case of hereditary histidine-rich glycoprotein deficiency with familial thrombophilia. Thromb Haemost 1996 ; 75 : 374-5.
PubMed
54) Shigekiyo T, Yoshida H, Kanagawa Y, et al. Histidinerich glycoprotein (HRG) Tokushima 2 : novel HRG deficiency, molecular and cellular characterization. Thromb Haemost 2000 ; 84 : 675-679.
PubMed
55) Engesser L, Kluft C, Briet E, et al. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol 1987 ; 67 : 355-358.
 
56) Angles-Cano E, Gris JC, Loyau S, Schved JF. Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism. J Lab Clin Med 1993 ; 121 : 646-653.
PubMed
57) Saito H, Goodnough LT, Boyle JM, et al. Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis. Am J Med 1982 ; 73 : 179-182.
PubMed
58) Saigo K, Yoshida A, Ryo R, et al. Histidine-rich glycoprotein as a negative acute phase reactant. Am J Hematol 1990 ; 34 : 149-150.
PubMed
59) Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemost 1982 ; 48 : 283-285.
PubMed
60) Lee KN, Tae WC, Jackson KW, et al. Characterization of wild-type and mutant alpha2-antiplasmins : fibrinolysis enhancement by reactive site mutant. Blood 1999 ; 94 : 164-171.
PubMed
61) Sakata Y, Eguchi Y, Mimuro J, et al. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor. Blood 1989 ; 74 : 2692-2697.
PubMed
P.104 掲載の参考文献
1) Birktoft JJ, Blow DM. Structure of crystalline -chymotrypsin. V. The atomic structure of tosyl- -chymotrypsin at 2 A resolution. J Mol Biol 1972 ; 68 : 187-240.
PubMed
2) Renatus M, Bode W, Huber R, et al. Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. J Biol Chem 1997 ; 272 : 21713-21719.
PubMed
3) West CW, Adler M, Arnaiz D, et al. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett 2009 ; 19 : 5712-5715.
 
4) Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors : structure, function, and regulation. J Biol Chem 1994 ; 269 : 15957-15960.
PubMed
5) Jankun J, Yang J, Zheng H, et al. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. Int J Mol Med 2012 ; 29 : 61-64.
 
6) Brogren H, Karlsson L, Andersson M, et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004 ; 104 : 3943-3948.
PubMed
7) Hakkert BC, Rentenaar JM, van Mourik JA. Monocytes enhance the bidirectional release of type I plasminogen activator inhibitor by endothelial cells. Blood 1990 ; 76 : 2272-2278.
PubMed
8) Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008 ; 14 : 1255-1260.
PubMed
9) Fay WP, Shapiro AD, Shih JL, et al. Brief report : complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992 ; 327 : 1729-1733.
PubMed
10) Iwaki T, Tanaka A, Miyawaki Y, et al. Lifethreatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011 ; 9 : 1200-1206.
PubMed
11) Iwaki T, Nagahashi K, Kobayashi T, et al. The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human. Thromb Res 2012 ; 129 : e161-e163.
 
12) Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation : a gene targeting and gene transfer study in mice. Circulation 1997 ; 96 : 3180-3191.
PubMed
13) Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 1989 ; 264 : 10867-10871.
PubMed
14) Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990 ; 249 : 1431-1433.
PubMed
15) Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001 ; 13 : 85-94.
PubMed
16) Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Haematologica 1999 ; 84 : 254-259.
PubMed
17) Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986 ; 163 : 1260-1266.
PubMed
18) Mestries JC, Kruithof EK, Gascon MP, et al. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994 ; 5 : 275-281.
PubMed
19) Burstein SA. Effects of interleukin 6 on megakaryocytes and on canine platelet function. Stem Cells 1994 ; 12 : 386-393.
PubMed
20) Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor 1 : a new prognostic marker in septic shock. Thromb Haemost 1989 ; 61 : 459-462.
PubMed
21) Madoiwa S, Nunomiya S, Ono T, et al. Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation. Int J Hematol 2006 ; 84 : 398-405.
PubMed
22) Murakami J, Ohtani A, Murata S. Protective effect of T-686, an inhibitor of plasminogen activator inhibitor-1 production, against the lethal effect of lipopolysaccharide in mice. Jpn J Pharmacol 1997 ; 75 : 291-294.
PubMed
23) Renckens R, Roelofs JJ, Bonta PI, et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007 ; 109 : 1593-1601.
PubMed
24) Rijneveld AW, Florquin S, Bresser P, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003 ; 102 : 934-939.
 
25) Bini A, Fenoglio JJ, Jr., Mesa-Tejada R, et al. Identification and distribution of fibrinogen, fibrin, and fibrin (ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989 ; 9 : 109-121.
PubMed
26) Lijnen HR, Collen D. Impaired fibrinolysis and the risk for coronary heart disease. Circulation 1996 ; 94 : 2052-2054.
PubMed
27) Zorio E, Gilabert-Estelles J, Espana F, et al. Fibrinolysis : the key to new pathogenetic mechanisms. Curr Med Chem 2008 ; 15 : 923-929.
PubMed
28) Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993 ; 13 : 1090-1100.
PubMed
29) Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat : possible contributor to vascular disease in obesity. Nat Med 1996 ; 2 : 800-803.
PubMed
30) Eitzman DT, Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000 ; 96 : 4212-4215.
PubMed
31) Sjoland H, Eitzman DT, Gordon D, et al. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 2000 ; 20 : 846-852.
PubMed
32) Zhu Y, Farrehi PM, Fay WP. Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation 2001 ; 103 : 3105-3110.
PubMed
33) Luttun A, Lupu F, Storkebaum E, et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002 ; 22 : 499-505.
PubMed
34) Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007 ; 27 : 1231-1237.
PubMed
35) 岩城孝行, 長橋ことみ. 先天性線溶因子異常症と妊娠. 産科と婦人科 2013 ; 80 (1) : 47-54.
Medical*Online
P.111 掲載の参考文献
1) 関泰一郎, 三浦徳, 細野崇. メタロカルボキシペプチダーゼTAFIの線溶抑制機能と病態生理. 日本血栓止血学会誌 2013 ; 24 (5) : 491-495.
 
2) 三浦徳, 細野崇, 関泰一郎. TAFIの構造と機能. 日本血栓止血学会誌 2014 ; 24 (5) : 512-515.
 
3) Hendriks D, Scharpe S, van Sande M, et al. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989 ; 27 : 277-285.
PubMed
4) Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989 ; 162 : 933-939.
 
5) Eaton DL, Malloy BE, Tsai SP, et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase-B from human plasma. J Biol Chem 1991 ; 266 : 21833-21838.
PubMed
6) Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995 ; 270 : 14477-14484.
 
7) Cote HCF, Stevens WK, Bajzar L, et al. Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A and R284A). J Biol Chem 1994 ; 269 : 11374-11380.
 
8) Vanhoof G, Wauters J, Schatteman K, et al. The gene for human carboxypeptidase U (CPU) - A proposed novel regulator of plasminogen activation-Maps to 13q14.11. Genomics 1996 ; 38 : 454-455.
PubMed
9) Wei SW, Segura S, Vendrell J, et al. Identification and characterization of three members of the human metallocarboxypeptidase gene family. J Biol Chem 2002 ; 277 : 14954-14964.
 
10) Barbosa Pereira PJ, Segura-Martin S, Oliva B, et al. Human procarboxypeptidase B : three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J Mol Biol 2002 ; 321 : 537-547.
PubMed
11) Willemse JL, Hendriks DF. Measurement of procarboxypeptidase U (TAFI) in human plasma : A laboratory challenge. Clin Chem 2006 ; 52 : 30-36.
PubMed
12) Boffa MB, Reid TS, Joo E. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor ; plasma procarboxypeptidase B). Biochemistry 1999 ; 38 : 6547-6558.
PubMed
13) Zhao L, Morser J, Bajzar L, et al. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms. Thromb Haemost 1998 ; 80 : 949-955.
PubMed
14) Brouwers GJ, Vos HL, Leebeek FW, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001 ; 98 : 1992-1993.
PubMed
15) Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI dependent. Blood 1996 ; 88 : 2093-2100.
PubMed
16) Mosnier LO, von dem Borne PAK, Meijers JCM, et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998 ; 80 : 829-835.
 
17) Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003 ; 101 : 4844-4846.
PubMed
18) Schadinger SL, Lin JH, Garand M, et al. Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. J Thromb Haemost 2010 ; 8 : 2523-2529.
PubMed
19) Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981 ; 78 : 2249-2252.
PubMed
20) Esmon NL, Owen WG, Esmon CT. Isolation of a membranebound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982 ; 257 : 859-864.
PubMed
21) Mishra N, Vercauteren E, Develter J. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Thromb Haemost 2011 ; 106 : 90-101.
PubMed
22) Vercauteren E, Mutch NJ, Declerck PJ, et al. Plasmin and the thrombin- thrombomodulin complex both contribute to TAFI activation in whole blood model thrombi. J Thromb Haemost 2013 ; 11 : 190-192.
 
23) Marx PF, Brondijk TH, Plug T, et al. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI : a novel mechanism for enzyme autoregulation. Blood 2008 ; 112 (7) : 2803-2809.
 
24) Anand K, Pallares I, Valnickova Z, et al. The crystal structure of thrombin-activable fibrinolysis inhibitor (TAFI) provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J Biol Chem 2008 ; 283 (43) : 29416-29423.
PubMed
25) Sanglas L, Valnickova Z, Arolas JL, et al. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. Mol Cell 2008 ; 31 (4) : 598-606.
PubMed
26) Sanglas L, Arolas JL, Valnickova Z, et al. Insights into the molecular inactivation mechanism of human activated thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010 ; 8 (5) : 1056-1065.
PubMed
27) Gils A. Hot spots in TAFIa. J Thromb Haemost 2010 ; 8 (5) : 1054-1055.
PubMed
28) Declerck PJ. Thrombin activatable fibrinolysis inhibitor. Hamostaseologie 2011 ; 31 (3) : 165-173.
PubMed
29) Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009 ; 7 (1) : 4-13.
PubMed
30) Foley JH, Kim PY, Mutch NJ, et al. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. J Thromb Haemost 2013 ; 11 Suppl 1 : 306-315.
 
31) Leurs J, Nerme V, Sim Y, et al. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004 ; 2 : 416-423.
PubMed
32) Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004 ; 279 : 27896-27904.
PubMed
33) Valnickova Z, Thogersen IB, Potempa J, et al. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J Biol Chem 2007 ; 282 : 3066-3076.
PubMed
34) Valnickova Z, Thogersen IB, Potempa J, et al. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolytic rate : reply to a rebuttal. J Thromb Haemost 2007 ; 5 : 1336-1337.
 
35) Willemse JL, Heylen E, Hendriks DF. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate : a rebuttal. J Thromb Haemost 2007 ; 5 : 1334-1336.
PubMed
36) Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008 ; 283 : 8863-8867.
 
37) van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000 ; 95 : 2855-2859.
PubMed
38) Libourel EJ, Bank I, Meinardi JR, et al. Co-segregation of thrombophilic disorders in factor V Leiden carriers ; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein (a) to the absolute risk of venous thromboembolism. Haematologica 2002 ; 87 : 1068-1073.
 
39) Juhan-Vague I, Morange PE. Very high TAFI antigen levels are associated with a lower risk of hard coronary events : the PRIME Study. J Thromb Haemost 2003 ; 1 : 2243-2244.
PubMed
40) Juhan-Vague I, Morange PE, Aubert H, et al. HIFMECH Study Group : Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002 ; 22 : 867-873.
 
41) Meltzer ME, Doggen CJ, de Groot PG, et al. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 2009 ; 94 : 811-818.
PubMed
42) Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003 ; 23 : 1122-1127.
PubMed
43) Ladenvall C, Gils A, Jood K, et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007 ; 27 : 955-962.
PubMed
44) Brouns R, Heylen E, Willemse JL, et al. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 2010 ; 8 : 75-80.
PubMed
45) Jood K, Redfors P, Gils A, et al. Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors. J Thromb Haemost 2012 ; 10 : 725-727.
PubMed
46) de Bruijne ELE, Gils A, Rijken DC, et al. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease. Thromb Res 2011 ; 127 : 254-258.
PubMed
47) Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010 ; 116 : 113-121.
PubMed
48) de Bruijne ELE, Gils A, Guimaraes AHC, et al. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age : the ATTAC study. J Thromb Haemost 2009 ; 7 : 919-927.
 
49) Tregouet DA, Schnabel R, Alessi MC, et al. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease : the AtheroGene study. J Thromb Haemost 2009 ; 7 : 49-57.
PubMed
50) Nagashima M, Yin ZF, Zhao L, et al. Thrombinactivatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002 ; 109 : 101-110.
 
51) Swaisgood CM, Schmitt D, Eaton D, et al. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002 ; 110 : 1275-1282.
PubMed
52) te Velde EA, Wagenaar GT, Reijerkerk A, et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003 ; 1 : 2087-2096.
PubMed
53) Mao SS, Holahan MA, Bailey C, et al. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul Fibrinolysis 2005 ; 16 : 407-415.
PubMed
54) Wang XK, Smith PL, Hsu MY, et al. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007 ; 23 : 41-49.
 
55) Vercauteren E, Peeters M, Hoylaerts MF, et al. The hyperfibrinolytic state of mice with combined TAFI and PAI-1 gene deficiency is critically dependent on TAFI deficiency. J Thromb Haemost 2012 ; 10 : 2555-2562.
PubMed
56) 奥村暢章, 関泰一郎, 有賀豊彦. TAFIと細胞線溶, 血栓止血誌 2009 ; 20 (4) : 406-411.
 
57) Okumura N, Koh T, Hasebe Y, et al. A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture. J Biol Chem 2009 ; 284 (24) : 16553-16561.
PubMed
P.116 掲載の参考文献
1) Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005 ; 129 (3) : 307-321.
PubMed
2) Hoylaerts M, Rijken DC, Lijnen HR, et al. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982 ; 257 (6) : 2912-2919.
PubMed
3) Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004 ; 279 (14) : 13333-13339.
PubMed
4) Willemse JL, Heylen E, Nesheim ME, et al. Carboxypeptidase U (TAFIa) : a new drug target for fibrinolytic therapy? J Thromb Haemost 2009 ; 7 : 1962-1971.
PubMed
5) Yoshimoto N, Sasaki T, Sugimoto K, et al. Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease. J Med Chem 2012 ; 55 : 7696-7705.
PubMed
6) Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999 ; 94 : 2735-2743.
PubMed
7) Nagashima M, Werner M, Wang M, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000 ; 98 : 333-342.
 
8) Wang YX, da Cunha V, Vincelette J, et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II : enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007 ; 97 : 54-61.
PubMed
9) Bird E, Tamura J, Bostwick JS, et al. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res. 2007 ; 120 : 549-558.
PubMed
10) Suzuki K, Muto Y, Fushihara K, et al. Enhancement of fibrinolysis by EF6265 [(S) -7-amino-2- [[[(R) -2-methyl-1- (3-phenylpropanoylamino) propyl] hydroxyphosphinoyl] methyl] heptanoic acid] , a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004 ; 309 : 607-615.
PubMed
11) Wang X, Smith PL, Hsu MY, et al. Murine model of ferric chloride-induced vena cava thrombosis : evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost 2006 ; 4 : 403-410.
PubMed
12) Eriksson H, Jensen E, Sandset PM, et al. CPU inhibition with AZD9684 : profibrinolytic effects in acute PE patients. J Thromb Haemost 2007 ; 5 Supplement 2 : P-S-367.
 
13) Bunnage ME, Blagg J, Steele J, et al. Discovery of potent & selective inhibitors of activated thrombinactivatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem 2007 ; 50 : 6095-6103.
PubMed
14) Noguchi K, Edo N, Ito Y, et al. DS-1040 : a novel selective inhibitor of activated form of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2015 ; 13 Supplement S2 : PO203.
 
15) Noguchi K, Edo N, Ito Y, et al. Effect of DS-1040 on endogenous fibrinolysis and impact on bleeding time in rats. J Thromb Haemost 2015 ; 13 Supplement S2 : AS145.
 
16) Zhou J, Zamora C, Atiee G, et al. A first-in-human, single ascending dose study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa), in healthy subjects. J Thromb Haemost 2015 ; 13 Supplement S2 : PO621.
 
17) Semeraro F, Ammollo CT, Gils A, et al. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. J Thromb Haemost. 2013 ; 11 : 2137-2147.
 
18) Denorme F, Wyseure T, Peeters M, et al. Inhibition of TAFI and PAI-1 is protective in a mouse model of cerebral ischemia/reperfusion injury. J Thromb Haemost 2015 ; 13 Supplement S2 : PO519
 
P.122 掲載の参考文献
1) Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995 Jul ; 74 (1) : 429-436.
PubMed
2) Lijinen HR. Matrix metalloproteinases and cellular fibrinolytic activity. Biochekmistry (Mosc) 2002 ; 67 : 92-98.
 
3) O'Reilly MS, Wiedershain D, Stetler ?Stenvensen WG, et al. Refulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999 ; 274 : 29568-29571.
 
4) Kanno Y, Kuroki A, Okada K, et al. Alpha2-antiplasmin is involved in the production of transforming growth factor beta1 and fibrosis. J Thromb Haemost 2007 ; 5 (11) : 2266-2273.
PubMed
5) Horowitz JC, Rogers DS, Simon RH, et al. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2008 Jan ; 38 (1) : 78-87.
PubMed
6) Samarakoon R, Overstreet JM, Higgins PJ. TGF-β signaling in tissue fibrosis : redox controls, target genes and therapeutic opportunities. Cell Signal 2013 ; 25 (1) : 264-268.
 
7) Noh H, Hong S, Huang S. Role of urokinase receptor in tumor progression and development. Theranostics 2013 ; 3 (7) : 487-495.
PubMed
8) Boyd D. Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Cancer Res 1989 ; 49 (9) : 2427-2432.
 
9) Lund LR1, Ellis V, Ronne E, et al. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 1995 ; 310 (Pt 1) : 345-352.
 
10) Lengyel E, Wang H, Gum R, et al. Elevated urokinasetype plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene 1997 ; 14 (21) : 2563-2573.
 
11) Gum R, Juarez J, Allgayer H, et al. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 1998 ; 17 (2) : 213-225.
PubMed
12) Duffy MJ. The urokinase plasminogen activator system : role in malignancy. Curr Pharm Des 2004 ; 10 : 39-49.
PubMed
13) Choong PF, and Nadesapillai AP. Urokinase plasminogen activator system : a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003 ; (415 Suppl) : S46-58.
 
14) Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, et al. The transcription factor nuclear factor-kappa B and cancer. lin Oncol (R Coll Radiol) 2007 ; 19 (2) : 154-161.
 
15) Pendurthi UR, Ngyuen M, Andrade-Gordon P, et al. Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogenactivated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol 2002 ; 22 (9) : 1421-1426.
PubMed
16) Majumdar M, Tarui T, Shi B, et al. Plasmin-induced migration requires signaling through protease-activated receptor 1 and integrin alpha (9) beta (1). J Biol Chem 2004 ; 279 (36) : 37528-37534.
PubMed
17) Samarakoon R, Overstreet JM, Higgins PJ. TGF-β signaling in tissue fibrosis : redox controls, target genes and therapeutic opportunities. Cell Signal. 2013 ; 25 (1) : 264-268.
 
18) Kanse SM, Kost C, Wilhelm OG, et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996 ; 224 (2) : 344-353.
 
19) Loridon-Rosa B, Vielh P, Cuadrado C, et al. Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am J Clin Pathol 1988 ; 90 : 7-16.
PubMed
20) Wu J, Strawn TL, Luo M, et al. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αV β 3 integrin cross talk. Arterioscler Thromb Vasc Biol 2015 ; 35 (1) : 111-120.
 
21) Crowley CW, Cohen RL, Lucas BK, et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993 ; 90 : 5021-5025
 
22) Mohanam S, Chandrasekar N, Yanamandra N, et al. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator. Oncogene 2002 ; 21 : 7824-7830.
PubMed
23) Hu XW, Duan HF, Gao LH, et al. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. CancerBiol Ther 2008 ; 7 : 651-659.
PubMed
24) Burgle M, Koppitz M, Riemer C, et al. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biological chemistry 1997 ; 378 : 231-237.
PubMed
25) Sato S, Kopitz C, Schmalix WA, et al. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction : effects on tumor growth and spread. FEBS Lett 2002 ; 528 : 212-216.
PubMed
26) Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002 ; 62 : 2390-2397.
PubMed
27) Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005 ; 65 : 7775-7781.
PubMed
28) Nikolova DA, Asangani IA, Nelson LD, et al. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer : u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 2009 ; 69 (6) : 2461-2470.
 
P.128 掲載の参考文献
1) Cines DB, Lebedeva T, Nagaswami C, et al. Clot contraction : compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 2014 ; 123 (10) : 1596-1603.
PubMed
2) Zalewski J, Bogaert J, Sadowski M, et al. Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction. Thromb Haemost 2015 ; 113 (6) : 1258-1269.
PubMed
3) Abdullahi Balarabe Sallau, Yusuf Tauhid, Abdullahi AbdulMalik et al. Effect of kihadalactone on plasma recalcification time of naja katiensis and bitis arietans venoms treated bovine plasma. Eur J Pharm Med Res, 2015 ; 2 (2) : 178-184.
 
4) Zalewski J, Bogaert J, Sadowski M, et al. Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction. Thromb Haemost 2015 ; 113 (6) : 1258-1269.
PubMed
5) Saha P, Humphries J, Modarai B, et al. Leukocytes and the natural history of deep vein thrombosis.current concepts and future directions. Arterioscler Thromb Vasc Biol. 2011 ; 31 : 506-512.
PubMed

書評

最近チェックした商品履歴

Loading...